RxDoctor Payments Data

Adam Kroe, MD

Family Medicine · Williamsville, NYNPI 1669039236

Payments from drug & device makers

$5,283in general payments, 2019–2025

Across 269 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$491
  • Boehringer Ingelheim$473
  • AstraZeneca$473
  • AbbVie$371
  • Exact Sciences$356
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,283100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,283 in reported general payments places this provider in the 85th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$35,778
Medicare patients
113
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide66$73,509
EliquisApixaban58$55,464
TrulicityDulaglutide31$43,314
JardianceEmpagliflozin32$31,527
OzempicSemaglutide23$22,607
FarxigaDapagliflozin Propanediol12$14,389
Rosuvastatin Calcium113$2,081
SynthroidLevothyroxine Sodium20$1,918
Fluticasone Propionate79$1,844
Albuterol Sulfate HfaAlbuterol Sulfate64$1,816
Atorvastatin Calcium119$1,734
Levothyroxine Sodium89$1,589
Metoprolol Succinate82$1,438
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,195
Amlodipine Besylate100$1,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,038$116,82397 claims
PfizerEliquis$281$55,46458 claims
Boehringer IngelheimJardiance$473$31,52732 claims
Novo NordiskOzempic$491$22,60723 claims
AstraZenecaFarxiga$473$14,38912 claims
AbbVieSynthroid$371$1,91820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,321 family medicine providers in New York.

Other family medicine in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →